Evidence map›Paper›PMID 40515396›Full record

ArticleClinical and experimental immunology2025

Uncovering metabolic pathways in human alveolar macrophages in response to lipopolysaccharide.

Christine C A van Linge, Erik H A Michels, Liza Pereverzeva, Regina de Beer, Augustijn M Klarenbeek, Bauke V Schomakers, Michel van Weeghel, Riekelt H Houtkooper, W Joost Wiersinga, Peter I Bonta and 3 more

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christine C A van LingeCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.ORCID 0000-0003-2787-8895
Erik H A MichelsCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
Liza PereverzevaCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.ORCID 0000-0001-9091-7506
Regina de BeerCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
Augustijn M KlarenbeekCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
Bauke V SchomakersLaboratory Genetic Metabolic Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
Michel van WeeghelLaboratory Genetic Metabolic Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.ORCID 0000-0002-4916-2866
Riekelt H HoutkooperLaboratory Genetic Metabolic Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
W Joost WiersingaCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
Peter I BontaDepartment of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1081 HV, the Netherlands.
Jouke T AnnemaDepartment of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1081 HV, the Netherlands.
Tom van der PollCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.ORCID 0000-0002-9199-5079
Alex F de VosCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.

Funding

European Union Horizon 2020 84778
6 · The paper itself

Abstract

introductionAlveolar macrophages (AMs) play an essential role in maintaining homeostasis in the lung and in innate immunity for host defense. To fuel inflammatory responses, AMs do not rely on glycolysis, but require oxidative phosphorylation. However, which nutrients AMs use to fuel their energy demand during inflammatory responses, is still unknown. The present study aimed to determine the contribution of three key metabolic pathways; fatty acid oxidation, glutaminolysis, and glycogenolysis, to the inflammatory response of AMs.

methodsPrimary AMs were isolated from healthy human volunteers and stimulated with lipopolysaccharide (LPS). After 24 hours, cells were subjected to analyses of metabolic flux, expression of genes involved in these metabolic pathways, and inflammatory cytokine secretion in the presence of metabolic inhibitors.

resultsThe results of our study show that human AMs display expression of genes involved in fatty acid and glutamine metabolism and are capable of metabolizing oleic acid and glutamine during homeostasis, but do not use these metabolites to fuel the production of inflammatory cytokines. We demonstrate that AMs, while residing in a glucose-deprived environment, contain glycogen and use glycogenolysis to fuel inflammatory cytokine secretion, as reflected by reduced TNF, IL-1β and IL-6 levels in supernatant of LPS-stimulated AMs treated with the glycogenolysis inhibitor CP316819. Moreover, AMs display marked expression of genes involved in glycogenesis, including FBP1 and GYS.

conclusionsTaken together, these results indicate that primary human AMs are equipped to use different nutrients to fuel their metabolic demands. Moreover, our findings suggest that glycogenolysis is critical for the inflammatory response of AMs.

Indexed as

LipopolysaccharidesMacrophages, AlveolarMetabolic Networks and PathwaysCells, CulturedCytokinesFatty AcidsGlutamineGlycogenolysisHumansInflammationMaleCytokinesFatty AcidsGlutamineLipopolysaccharidescellular immunologylipopolysaccharidemacrophagemetabolism

Identifiers

PMID40515396
PMCPMC12232543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.